You know the feeling: you read a Q-bank vignette, pick the right answer… and still miss the next question because you didn’t really understand why the distractors were wrong. 5-alpha reductase deficiency is a classic “answer-choice trap” topic—because it sits right at the intersection of embryology, steroid biochem, and clinical presentation. Let’s break it down the way Q-banks test it: one vignette, one correct answer, and every distractor gets a purpose.
Tag: Reproductive > Male Reproductive
The Clinical Vignette (Classic Q-Bank Style)
A 16-year-old individual raised as female presents with primary amenorrhea and “new” virilization at puberty, including deepening of the voice and increased muscle mass. On exam, there is sparse breast development, scant axillary hair, and ambiguous genitalia with a small phallus-like structure. Palpable gonads are present in the inguinal canal. Ultrasound shows no uterus or ovaries. Labs: testosterone is in the male range; DHT is low.
Question: What is the most likely underlying enzyme deficiency?
The Correct Answer: 5-alpha Reductase Deficiency
What the enzyme does (high-yield)
5-alpha reductase converts:
- Testosterone → Dihydrotestosterone (DHT)
DHT is the “external genitalia and prostate” androgen:
- External male genitalia (penis, scrotum) development in utero
- Prostate development
- Some secondary sex characteristics (e.g., body hair patterns)
Pathophysiology that explains the vignette
In 46,XY individuals:
- Testosterone is normal/high → internal male ducts develop normally (because Wolffian structures need testosterone, not DHT)
- DHT is low → external genitalia undervirilized/ambiguous at birth
- AMH is normal (from Sertoli cells) → no uterus / no fallopian tubes
At puberty:
- Testosterone rises → virilization occurs (voice deepens, muscle mass increases)
- But DHT-dependent changes remain limited, often including:
- Small prostate
- Less facial/body hair
- Variable genital virilization
Key exam clue set
If you see:
- 46,XY
- No uterus
- Ambiguous external genitalia
- Virilization at puberty
- Low DHT / high (or normal) testosterone → think 5-alpha reductase deficiency
High-yield lab pearl: Testosterone:DHT ratio
A common teaching point is an increased testosterone:DHT ratio, especially after hCG stimulation testing (institution-dependent in practice, but very Step-friendly conceptually).
Why Every Answer Choice Matters (Systematic Distractor Breakdown)
Below are the most common “near-miss” answer choices and how to eliminate them quickly.
Distractor 1: Androgen Insensitivity Syndrome (AIS)
Why it tempts you: also 46,XY; also no uterus; also often raised female.
But here’s the difference: AIS = androgen receptor defect, so tissues can’t respond to testosterone or DHT.
Classic AIS findings
- Phenotypic female external genitalia (often normal-appearing)
- Sparse/absent pubic and axillary hair (androgen-dependent)
- Breast development present at puberty (testosterone aromatized → estrogen)
- Undescended testes
- No uterus (AMH still present)
How to distinguish from 5-AR deficiency
| Feature | 5-alpha reductase deficiency | AIS |
|---|---|---|
| External genitalia at birth | Ambiguous/undervirilized | Female (often normal) |
| Puberty | Virilization (voice deepens, etc.) | No virilization |
| Breast development | Typically minimal | Present/normal |
| Pubic/axillary hair | Often present (variable) | scant/absent |
| Key problem | Low DHT | Androgen receptor nonfunctional |
One-liner: AIS patients can’t respond to testosterone, so they don’t virilize at puberty—that’s the giveaway.
Distractor 2: 17-beta Hydroxysteroid Dehydrogenase Deficiency
Why it tempts you: another cause of undervirilized 46,XY with ambiguous genitalia.
What it does This enzyme helps convert androstenedione → testosterone (and estrone → estradiol).
Expected outcome
- Low testosterone → impaired Wolffian development and undervirilized external genitalia
- Can have undervirilized genitalia and may be raised female
- Puberty may bring some virilization, but the biochemical signature differs
How to eliminate
Your vignette says testosterone is in the male range with low DHT.
That points downstream of testosterone production (5-alpha reductase), not upstream.
Distractor 3: 5-alpha Reductase Inhibitor Exposure (Finasteride/Dutasteride)
Why it tempts you: it literally causes “functional 5-alpha reductase deficiency.”
Key concept
- Finasteride inhibits 5-alpha reductase (commonly type II)
- Can lead to ambiguous genitalia in a male fetus if exposure occurs during pregnancy
How to eliminate Q-banks usually distinguish by context:
- Medication exposure history (pregnant parent on finasteride/dutasteride)
- Often asked as a pharmacology teratogenicity question
If the question asks for enzyme deficiency or implies a genetic DSD, pick the inherited condition—unless medication exposure is explicitly highlighted.
Distractor 4: 11-beta Hydroxylase Deficiency (Congenital Adrenal Hyperplasia)
Why it tempts you: causes androgen excess and virilization.
But note the patient
- Your patient is 46,XY with undervirilized external genitalia at birth and no uterus.
- CAH classically causes:
- Virilization of 46,XX infants
- In 46,XY: typically normal male genitalia, maybe precocious puberty (not ambiguous genitalia)
Extra clue: 11β-hydroxylase CAH causes:
- HTN (due to DOC excess)
- Low renin
- Low aldosterone
- High androgens
Not the same story.
Distractor 5: 21-hydroxylase Deficiency (Congenital Adrenal Hyperplasia)
Why it tempts you: the most common CAH; lots of virilization talk.
Why it’s wrong here 21-hydroxylase deficiency leads to:
- Cortisol low → ACTH high → adrenal hyperplasia
- Aldosterone low → salt-wasting, hyperkalemia, hypotension (in classic form)
- Androgens high
But 46,XY individuals generally have normal male external genitalia (since they already have testes making testosterone/DHT). The “ambiguous genitalia” CAH red flag is usually 46,XX.
Distractor 6: Leydig Cell Dysfunction (e.g., LH receptor defect)
Why it tempts you: would reduce testosterone, causing undervirilization.
Why it’s wrong Leydig cell failure → low testosterone → would impair:
- Wolffian duct development (internal male structures)
- virilization at puberty
But the vignette gives testosterone in the male range and focuses on low DHT, making the problem specifically conversion to DHT, not testosterone synthesis.
Distractor 7: Persistent Müllerian Duct Syndrome (AMH or AMH receptor defect)
Why it tempts you: “palpable testes + reproductive tract anomalies” can lead people astray.
What it actually causes
- 46,XY with normal male external genitalia
- Uterus and fallopian tubes present (because AMH signaling fails)
- Often discovered during hernia repair/cryptorchidism workup
How to eliminate Your vignette shows no uterus. That means AMH is doing its job, so persistent Müllerian duct syndrome is out.
Rapid-Fire USMLE High-Yield Summary
5-alpha reductase deficiency: memorize these anchors
- 46,XY
- Normal testes, often undescended/inguinal
- No uterus (AMH intact)
- Ambiguous external genitalia at birth
- Virilization at puberty (testosterone surge)
- ↓ DHT, ↑ testosterone:DHT ratio
- Small/underdeveloped prostate
Steroid pathway “directionality” trick
If testosterone is normal/high but virilization is incomplete in utero, think:
- Can’t make DHT (5-alpha reductase deficiency)
or - Can’t respond to androgens (AIS; but then puberty virilization won’t happen)
Mini Table: Fast Differentiation (Common Step Pair)
| Condition | Karyotype | Uterus? | External genitalia | Puberty | Key labs |
|---|---|---|---|---|---|
| 5-alpha reductase deficiency | 46,XY | No | Ambiguous/undervirilized | Virilizes | ↓ DHT, T normal/high |
| AIS | 46,XY | No | Female (often normal) | Breasts develop, no virilization | Androgens high, AR resistance |
Takeaway: How Q-Banks Want You to Think
When a vignette screams “46,XY + no uterus,” you’re in testes + AMH working territory. From there, the external genitalia and puberty pattern tells you whether the issue is:
- DHT production (5-alpha reductase deficiency)
vs - androgen response (AIS)
That’s why every distractor matters: they’re testing whether you can localize the defect to hormone production, conversion, or receptor signaling—and do it fast.